Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents a systematic review and meta-analysis

Annals of Internal Medicine

Volumn 163, Issue 10, 2015, Pages 756-767

  Miligkos, Michael ^a   Bannuru, Raveendhara R ^b   Alkofide, Hadeel ^c   Kher, Sucharita R ^d   Schmid, Christopher H ^e   Balk, Ethan M ^e  

^a UNIVERSITY OF THESSALY   (Greece)

^b TUFTS MEDICAL CENTER   (United States)

^c TUFTS UNIVERSITY   (United States)

^d Pulmonary and Critical Care Division   (United States)

^e BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PRANLUKAST; ZAFIRLUKAST; ANTIASTHMATIC AGENT;

ADD ON THERAPY; ADOLESCENT; ADULT; AROUSAL; ASTHMA; CORTICOSTEROID THERAPY; DISEASE CONTROL; DRUG TOLERABILITY; DRUG USE; FORCED EXPIRATORY VOLUME; HUMAN; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; COMBINATION DRUG THERAPY; DISEASE COURSE; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84947427115     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1059     Document Type: Review

References (75)

1. Asthma and Allergy Foundation of America. Cost of Asthma. Accessed at www.aafa.org/display.cfm?id=6&sub=63 on 28 August 2015.
2. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-78. [PMID: 15080825]
3. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196-208. [PMID: 7847437]
4. Philip G, Nayak AS, Berger WE, Leynadier F, Vrijens F, Dass SB, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin. 2004;20:1549-58. [PMID: 15462688]
5. European Network for Understanding Mechanisms of Severe Asthma. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. Eur Respir J. 2003;22:470-7. [PMID: 14516137]
6. Global Initiative for Asthma. 2012 Update: Global Strategy for Asthma Management and Prevention. Accessed at www.ginasthma.org/documents/5/documents-variants/37/on 28 August 2015.
7. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83. [PMID: 1549827]
8. Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J. 1999;14:32-8. [PMID: 10489826]
9. Wallace BC, Small K, Brodley CE, Lau J, Trikalinos TA. Deploying an interactive machine learning system in an evidence-based practice center: abstrackr [Abstract]. In: Proceedings of the 2nd Association for Computing Machinery Special Interest Group in Health Informatics International Health Informatics Symposium, Miami, Florida, 28-30 January 2012. New York: Association for Computing Machinery; 2012:819-24.
10. Ip S, Hadar N, Keefe S, Parkin C, Iovin R, Balk EM, et al. A Webbased archive of systematic review data. Syst Rev. 2012;1:15. [PMID: 22588052] doi:10.1186/2046-4053-1-15
11. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, UK: Wiley; 2008:187-241.
12. Cooper H, Hedges LV, eds. The Handbook of Research Synthesis. 1st ed. New York: Russell Sage Foundation; 1994.
13. Balk EM, Earley A, Patel K, Trikalinos TA, Dahabreh IJ. Empirical Assessment of Within-Arm Correlation Imputation in Trials of Continuous Outcomes. Report no. 12 (13)-EHC141-EF.. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
14. Engauge Digitizer Qt4. Accessed at http://digitizer.sourceforge.net on 1 February 2015.
15. Raudenbush SW, Bryk AS. Empirical Bayes meta-analysis. J Educ Stat. 1985;10:75-98.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
17. Murphy S, Sheffer AL, Pauwels R. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.. National Institutes of Health publication no. 07-4051. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007. Accessed at www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf on 28 August 2015.
18. OpenMeta[Analyst]. Accessed at www.cebm.brown.edu/open-meta/on 14 May 2015.
19. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol. 1998;102:50-6. [PMID: 9679847]
20. American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007;175:235-42. [PMID: 16998094]
21. Awad N, Joshi J, Naidu MUR, Airan C, Ushurani P, Singhal P, et al. Comparative evaluation of the efficacy of zafirlukast 20 mg tablets versus placebo in patients with mild to moderate asthma. Indian Pract. 2002;55:303-22.
22. Baena-Cagnani CE, Berger WE, Du Buske LM, Gurné SE, Stryszak P, Lorber R, et al. Comparative effects of desloratadine versus montelukast on asthma symptoms and use of beta 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003;130:307-13. [PMID: 12740532]
23. Barnes NC, Pujet JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax. 1997;52:523-7. [PMID: 9227718]
24. Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, et al; Montelukast Asthma Study Group. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J. 2003;21:123-8. [PMID: 12570120]
25. Busse W, Wolfe J, Storms W, Srebro S, Edwards L, Johnson M, et al. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. J Fam Pract. 2001;50:595-602. [PMID: 11485708]
26. Cakmak G, Demir T, Gemicioglu B, Aydemir A, Serdaroglu E, Donma O. The effects of add-on zafirlukast treatment to budesonide on bronchial hyperresponsiveness and serum levels of eosinophilic cationic protein and total antioxidant capacity in asthmatic patients. Tohoku J Exp Med. 2004;204:249-56. [PMID: 15572850]
27. Capriles Hulett A, Yibirin MG, Garcia A, Hurtado D. Montelukast for the high impact of asthma exacerbations in Venezuela: a practical and valid approach for Latin America? World Allergy Organiz J. 2014;7:20.
28. Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:9-14. [PMID: 11779723]
29. Fish JE, Kemp JP, Lockey RF, Glass M, Hanby LA, Bonuccelli CM. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther. 1997;19:675-90. [PMID: 9377612]
30. Gao JM, Cai F, Peng M, Ma Y, Wang B. Montelukast improves air trapping, not airway remodeling, in patients with moderate-tosevere asthma: a pilot study. Chin Med J (Engl). 2013;126:2229-34. [PMID: 23786930]
31. Green RH, Brightling CE, McKenna S, Hargadon B, Neale N, Parker D, et al. Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness. Eur Respir J. 2006;27:1144-51. [PMID: 16455831]
32. Helenius I, Lumme A, Ounap J, Obase Y, Rytilä P, Sarna S, et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. Allergy. 2004;59:39-44. [PMID: 14674932]
33. Huang CJ, Wang CH, Liu WT, Yang MC, Lin HC, Yu CT, et al. Zafirlukast improves pulmonary function in patients with moderate persistent asthma receiving regular inhaled steroids: a prospective randomized control study. Chang Gung Med J. 2003;26:554-60. [PMID: 14609035]
34. Israel E, Chervinsky PS, Friedman B, Van Bavel J, Skalky CS, Ghannam AF, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol. 2002;110:847-54. [PMID: 12464949]
35. Jayaram L, Duong M, Pizzichini MM, Pizzichini E, Kamada D, Efthimiadis A, et al. Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. Eur Respir J. 2005;25:41-6. [PMID: 15640321]
36. Jayaram L, Pizzichini E, Lemière C, Man SF, Cartier A, Hargreave FE, et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax. 2005;60:100-5. [PMID: 15681495]
37. Kanazawa H, Yoshikawa T, Hirata K, Yoshikawa J. Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients. Chest. 2004;125:1700-5. [PMID: 15136379]
38. Kanniess F, Richter K, Janicki S, Schleiss MB, Jörres RA, Magnussen H. Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma. Eur Respir J. 2002;20:1080-7. [PMID: 12449158]
39. Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest. 2006;130:1726-32. [PMID: 17166989]
40. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999;160:1862-8. [PMID: 10588598]
41. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-52. [PMID: 9664090]
42. Löfdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, Finn AF, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319:87-90. [PMID: 10398629]
43. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Piñeiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130:487-95. [PMID: 10075616]
44. Minoguchi K, Kohno Y, Minoguchi H, Kihara N, Sano Y, Yasuhara H, et al. Reduction of eosinophilic inflammation in the airways of patients with asthma using montelukast. Chest. 2002;121:732-8. [PMID: 11888953]
45. Nakamura Y, Hoshino M, Sim JJ, Ishii K, Hosaka K, Sakamoto T. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma. Thorax. 1998;53:835-41. [PMID: 10193369]
46. Nathan RA, Bernstein JA, Bielory L, Bonuccelli CM, Calhoun WJ, Galant SP, et al. Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction. J Allergy Clin Immunol. 1998;102:935-42. [PMID: 9847434]
47. Nathan RA, Minkwitz MC, Bonuccelli CM. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Ann Allergy Asthma Immunol. 1999;82:497-503. [PMID: 10353583]
48. Nathan RA, Yancey SW, Waitkus-Edwards K, Prillaman BA, Stauffer JL, Philpot E, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128:1910-20. [PMID: 16236835]
49. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 1999;14:12-8. [PMID: 10489822]
50. Price D, Popov TA, Bjermer L, Lu S, Petrovic R, Vandormael K, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131:763-71. [PMID: 23380218] doi: 10.1016/j.jaci.2012.12.673
51. Reid DW, Misso NL, Aggarwal S, Thompson PJ, Johns DP, Walters EH. Tolerance and rebound with zafirlukast in patients with persistent asthma. J Negat Results Biomed. 2008;7:3. [PMID: 18489783] doi:10.1186/1477-5751-7-3
52. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158:1213-20. [PMID: 9625400]
53. Schäper C, Noga O, Koch B, Ewert R, Felix SB, Gläser S, et al. Anti-inflammatory properties of montelukast, a leukotriene receptor antagonist in patients with asthma and nasal polyposis. J Investig Allergol Clin Immunol. 2011;21:51-8. [PMID: 21370724]
54. Spahn JD, Covar RA, Jain N, Gleason M, Shimamoto R, Szefler SJ, et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol. 2006;96:541-9. [PMID: 16680924]
55. Spector SL, Smith LJ, Glass M. Effects of 6 weeks of therapy with oral doses of ICI 204, 219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med. 1994;150:618-23. [PMID: 8087328]
56. Spector SL, Tan RA. Effectiveness of montelukast in the treatment of cough variant asthma. Ann Allergy Asthma Immunol. 2004;93:232-6. [PMID: 15478381]
57. Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of antiasthma treatment on lung function in children with asthma. Pulm Pharmacol Ther. 2007;20:691-700. [PMID: 17046300]
58. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of glucocorticoid, antileukotriene and beta-agonist treatment on IL-10 serum levels in children with asthma. Clin Exp Allergy. 2002;32:264-9. [PMID: 11929492]
59. Stelmach I, Jerzynska J, Kuna P. A randomized, double-blind trial of the effect of treatment with montelukast on bronchial hyperresponsiveness and serum eosinophilic cationic protein (ECP), soluble interleukin 2 receptor (sIL-2R), IL-4, and soluble intercellular adhesion molecule 1 (sICAM-1) in children with asthma. J Allergy Clin Immunol. 2002;109:257-63. [PMID: 11842294]
60. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med. 2004;98:1051-62. [PMID: 15526805]
61. Strunk RC, Bacharier LB, Phillips BR, Szefler SJ, Zeiger RS, Chinchilli VM, et al; CARE Network. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-to-severe childhood asthma study. J Allergy Clin Immunol. 2008;122:1138-1144. e4. [PMID: 18951618] doi:10.1016/j.jaci.2008.09.028
62. Tohda Y, Fujimura M, Taniguchi H, Takagi K, Igarashi T, Yasuhara H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients. Clin Exp Allergy. 2002;32:1180-6. [PMID: 12190656]
63. Ulrik CS, Diamant Z. Effect of montelukast on excessive airway narrowing response to methacholine in adult asthmatic patients not on controller therapy. Allergy Asthma Proc. 2009;30:64-8. [PMID: 19331721] doi:10.2500/aap. 2009.30.3196
64. Vaquerizo MJ, Casan P, Castillo J, Perpiña M, Sanchis J, Sobradillo V, et al; CASIOPEA (Capacidad de Singulair Oral en la Prevencion de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58:204-10. [PMID: 12612294]
65. Wise RA, Bartlett SJ, Brown ED, Castro M, Cohen R, Holbrook JT, et al; American Lung Association Asthma Clinical Research Centers. Randomized trial of the effect of drug presentation on asthma outcomes: the American Lung Association Asthma Clinical Research Centers. J Allergy Clin Immunol. 2009;124:436-44, 444e1-8. [PMID: 19632710] doi:10.1016/j.jaci.2009.05.041
66. Yoo SH, Park SH, Song JS, Kang KH, Park CS, Yoo JH, et al; Representing Korea Pranlukast Study Group. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma: a 4 week randomized multicentre controlled trial. Respirology. 2001;6:15-21. [PMID: 11264758]
67. Yoshida S, Ishizaki Y, Shoji T, Onuma K, Nakagawa H, Nakabayashi M, et al. Effect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy. 2000;30:1008-14. [PMID: 10848924]
68. Zeidler MR, Kleerup EC, Goldin JG, Kim HJ, Truong DA, Simmons MD, et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur Respir J. 2006;27:307-15. [PMID: 16452585]
69. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008;63:453-62. [PMID: 18443162] doi:10.1136/thx.2007.081596
70. Ducharme FM. Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ. 2002;324:1545. [PMID: 12089089]
71. Currie GP, Lipworth BJ. Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest. 2002;122:146-50. [PMID: 12114350]
72. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120:S94-138. [PMID: 17983880]
73. Storms W, Michele TM, Knorr B, Noonan G, Shapiro G, Zhang J, et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy. 2001;31:77-87. [PMID: 11167954]
74. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368:804-13. [PMID: 16935691]
75. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59-65. [PMID: 14713908]